Next Generation Cancer Diagnostics: Technologies and Global Markets

Sep 2020| BIO081C| BCC Publishing
Report Overview

Report Highlights

The global market for next generation cancer diagnostics is expected to grow from $6.2 billion in 2020 to $16.7 billion by 2025 with a compound annual growth rate (CAGR) of 21.9% for the period of 2020-2025.

Report Includes

  • 22 data tables and 74 additional tables
  • An overview of the global market and technologies for next generation cancer diagnostics
  • Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Analyses of the next generation cancer diagnostics market by cancer site, analysis purpose, analysis platform and region
  • Discussion on arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
  • Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios of the cancer diagnostics market
  • Discussion on factors affecting the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses
  • Details of the key initiatives and programs related to the next generation cancer diagnostics market
  • Market share analysis of the key companies of the industry, their strategic profiling, competitive landscape, and their detailed company profiles, including Abbott Laboratories, Illumina Inc., Myriad Genetics Inc., Qiagen NV, Oche Holding AG, and Thermo Fisher Scientific Inc.

Report Scope

The scope of this report includes next generation diagnostic technologies, applications, industry subsegments, major funding initiatives, patents and companies. The market sizes for next generation cancer diagnostics are given for 2019, 2020 (estimated) and 2025 (forecasted).

This report reviews the main next generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture and arrays/microfluidics. The report also discusses, in-depth, various liquid biopsy platforms and how these compare with tissue-based testing.

The report discusses several significant, large-scale research initiatives that contribute to cancer diagnostic development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from Jan. 2019 through June 2020. The industry subsectors analyzed include DNA sequencing instruments, long-read DNA sequencing, informatics, PCR, droplet digital PCR, CTC capture and detection and liquid biopsy.

The market for next generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia Pacific, Rest of World).

Market data covers 2019, 2020 (estimated) and 2025 (forecasted).

There is a special section discussing the impact of COVID-19 on the market for next generation cancer diagnostics.

More than 130 companies in the next generation cancer diagnostics industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from Jan. 2019 through June 2020, including key alliance trends.

 

Analyst Credentials

John Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a nanotechnology/separations company. Bergin holds a B.S. degree in Chemistry, an M.S. degree in Biotechnology and a Master of Business Administration. John Bergin is a pseudonym of the author.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesPrice Member Price
Full Report: Next Generation Cancer Diagnostics: Technologies and Global Markets318 $5,500 Free
Chapter- 1: Introduction9Free DownloadFree
Chapter- 2: Summary and Highlights4$250Free
Chapter- 3: Overview7$121Free
Chapter- 4: Technologies13$225Free
Chapter- 5: Liquid Biopsy Technologies16$277Free
Chapter- 6: Next Generation Cancer Diagnostics: Key Initiatives and Programs15$259Free
Chapter- 7: Next Generation Cancer Diagnostic Applications by Cancer Site57$986Free
Chapter- 8: Cancer Diagnostics Industries30$519Free
Chapter- 9: Industry Acquisitions and Strategic Alliances9$156Free
Chapter- 10: Cancer Diagnostics Markets64$1,107Free
Chapter- 11: Patents5$86Free
Chapter- 12: Company Profiles89$1,539Free
Published - Aug-2014| Analyst - John Bergin| Code - BIO081B

Report Highlights

BCC Research estimates the global market for next generation cancer diagnostic as $1.6 billion in 2013. This indication is expected to reach $1.8 billion in 2014 and $10 billion in 2019, registering a compound annual growth (CAGR) of 42.6% over the next five years.

Report Includes

  • An overview of the global market for next generation cancer diagnostics and related technologies.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Analyses of the diagnostics market by cancer indication (e.g., breast, colorectal, prostate, etc.), by type of analysis (e.g., gene expression, genotyping, proteomic, etc.), and by diagnostic function (e.g., screening/early detection, prognosis, monitoring/recurrence, and companion diagnostic).
  • Examination of each technology format to determine its market status, impact on future market segments, and projected growth through the forecast period.
  • Discussion on factors influencing the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses.
  • Assessments of the major next generation formats that are likely to become commercialized within the next five years.
  • Profiles of companies in the industry as well as a look at corporate alliances.
Published - Apr-2011| Analyst - John Bergin| Code - BIO081A

Report Highlights

The total global annual market for next generation cancer diagnostics was $776 million in 2010, and is growing at a compound annual growth rate (CAGR) of 47%, to reach a forecast market size of $5.3 billion in 2015.

Next Generation Cancer Diagnostics: Technologies and Global Markets

Single User License: $5500

Member Price: FREE

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report